Cancer Misdiagnosis in Ireland: Proving a Claim When the System Fails

What counts as cancer misdiagnosis under Irish law?

Cancer misdiagnosis under Irish law doesn't require intent. It means a healthcare professional didn't detect, correctly identify, or appropriately act on cancer at a point when a reasonably competent practitioner of equal specialist status would have done so, applying ordinary care. This is the Dunne test, established in Dunne v National Maternity Hospital [1989] IR 91 and reaffirmed by the Supreme Court in Morrissey v HSE [2020] IESC 6 (BAILII).

The error can take several forms: a GP who dismisses persistent symptoms as IBS or anxiety when red-flag criteria for urgent referral are met. A radiologist who misreads a lung nodule on CT. A pathologist who underclassifies a biopsy grade. An administrator who files an abnormal result without recalling the patient. Not every missed cancer is negligent. Cancer biology is complex and some presentations are genuinely atypical. The claim turns on whether the professional's conduct fell below what their peers would accept as competent practice in 2025.

Unlike in England and Wales, where the Bolam/Bolitho test applies, Irish courts use the Dunne principles as the sole standard for clinical negligence. A key distinction: the Dunne test requires that no medical practitioner of equal standing would have made the error, whereas Bolam asks whether a responsible body of opinion would support the practice. In screening cases, the bar is higher still (see Morrissey below).

How the system fails: referral, radiology, pathology

Cancer misdiagnosis in Ireland rarely stems from a single human error. It typically involves a chain of failures across at least one of three stages. Understanding where the breakdown occurred is central to proving breach of duty.

Referral pathway failures

GPs can't ignore the National Cancer Control Programme (NCCP) referral guidelines, which set out "red flag" symptoms triggering urgent referral via the Healthlink electronic system. A patient coughing blood should be flagged for an urgent lung Rapid Access Clinic appointment. When a GP marks that referral as "routine" instead, or sends a letter rather than using the electronic pathway, that's a measurable deviation from the standard of care. What's often overlooked: negligence sometimes begins not with the GP but at hospital triage, where a consultant may downgrade an urgent referral to routine based on incomplete information.

Radiology and IT failures

Diagnostic imaging errors are the single largest category of diagnostic error claims managed by the State Claims Agency. These aren't always perception errors by radiologists. The National Integrated Medical Imaging System (NIMIS), the HSE's radiology archiving platform, had a documented flaw where the < symbol was omitted from archived reports. A report reading "nodule <10mm" (suggesting benign monitoring) could appear as "nodule 10mm" (suggesting possible malignancy requiring action), or the reverse. This kind of IT-driven error creates a distinct liability profile: the failure sits with the system rather than the individual clinician.

Pathology and laboratory errors

The final diagnosis rests on tissue examined under a microscope. Errors here aren't rare: misgrading a tumour, confusing benign and malignant cells, or failing to request additional staining. Irish laboratories operate under ISO 15189 accreditation standards. The CervicalCheck scandal exposed that samples had been outsourced to laboratories in the United States (Quest Diagnostics) and Ireland (Medlab) that operated under different sensitivity thresholds from those required by Irish screening standards. The Supreme Court examined this directly in Morrissey.

What symptoms should have triggered an urgent cancer referral?

The NCCP publishes referral guidelines for each Rapid Access Clinic. These aren't suggestions. They're the standard your GP was measured against. In a negligence claim, they define the minimum standard of care your GP was expected to follow. If your symptoms matched the criteria below and your GP didn't refer urgently, that's a measurable deviation from the standard. The question isn't whether your GP thought it was cancer. It's whether the symptoms required urgent investigation under the guidelines they're trained to follow.

Two practical points. First, the electronic referral via Healthlink is the expected pathway. A GP who sends a letter instead of using the electronic system introduces delay. It's entirely avoidable and documentable. Second, the "urgent" classification matters: if your GP referred you but marked it as routine rather than urgent, the hospital triage system may've added weeks or months to your waiting time. That downgrading decision is itself a potential breach if your symptoms met the red-flag criteria.

In practice, the strongest breach-of-duty evidence often isn't a missed diagnosis. It's a missed referral. The GP's own clinical notes will record the symptoms you presented with. If those symptoms appear in the table above and the referral wasn't urgent, that gap speaks for itself. You don't need a medical expert to make that point.

The Morrissey ruling: why screening standards are higher

The Supreme Court in Morrissey & Anor v Health Service Executive & Ors [2020] IESC 6 delivered a unanimous five-judge ruling that remains the defining authority for cancer screening negligence in Ireland (full judgment). The court confirmed the Dunne principles as the correct legal test but didn't apply them loosely. It held them with particular force to screening: a screener mustn't clear a slide if there's any doubt about whether the sample is adequate or contains suspicious material.

A point worth emphasising: the HSE's non-delegable duty means that for any State-run screening programme, the HSE itself is primarily liable for the negligence of contracted laboratories. This principle extends beyond CervicalCheck to BreastCheck and BowelScreen.

TNM staging shift: turning delay into provable damage

Proving causation in cancer claims isn't just about showing a missed diagnosis. Irish law requires proof that the negligence caused a distinct, quantifiable injury beyond the underlying disease. The standard method is demonstrating a TNM staging shift, the measurable worsening of cancer stage between when it should have been found and when it was actually diagnosed. See NCRI cancer factsheets for Irish staging data.

The "injury" in legal terms is that delta, the difference in prognosis, treatment burden, and life expectancy caused by the staging shift. An independent oncology expert quantifies this by comparing what treatment would have been needed at the earlier stage versus what was actually required. This is where your medical records, histology reports, and imaging timeline become central evidence.

Between assessment and settlement in cancer claims, the sticking point usually isn't breach — it's causation. Defence teams often argue the cancer was biologically aggressive enough to have progressed regardless of earlier detection. Your expert must demonstrate, on the balance of probabilities, that timely detection would have led to a materially better outcome.

How hospitals attack your causation evidence (the Goldilocks defence)

Defence teams in cancer misdiagnosis claims don't just dispute whether the diagnosis was missed. They'll attack causation by targeting tumour doubling time evidence. This strategy, sometimes called the Goldilocks defence, works both ways.

Tumour doubling time is the period a cancer takes to double in volume. Many Irish claims rely on the Peer Paper (Peer et al., Cancer, 1993: PubMed 8490903). It's a widely cited study of 289 breast cancers used for decades in medico-legal practice. Defence experts increasingly challenge it. Their argument runs like this. If the doubling time is slow (say 120+ days), the cancer wasn't aggressive and the delay didn't materially change your prognosis. If the doubling time is fast (under 50 days), the cancer was so aggressive it couldn't have been detected earlier. Either way, the defence says the delay didn't matter. It's a heads-I-win, tails-you-lose argument.

In a 2023 High Court judgment involving Letterkenny University Hospital, Ms Justice Gearty rejected a plaintiff's expert evidence that relied on the Peer Paper, finding the expert had "espoused the plaintiff's case too closely" and that the Peer data wasn't reliable enough to establish causation. The defence argued the cancer was an interval cancer (growing between screening appointments) rather than a missed finding.

The practical lesson: your oncology expert can't just cite the Peer Paper and declare a doubling time. That's not enough. They need to triangulate with imaging comparison, clinical staging records, and an independent analysis of what was visible at each time point. Weak expert reports that marry themselves to one dataset are exactly what defence teams are trained to dismantle. If your expert hasn't addressed the Goldilocks argument head-on, they're vulnerable.

What if your cancer was already advanced? The loss of chance problem in Irish law

This is the hardest question in cancer misdiagnosis claims, and Irish law hasn't fully resolved it. If your cancer was already at stage III or IV when it should have been caught, the hospital's defence will argue. They'll say: "even with earlier diagnosis, the prognosis was poor. The delay didn't cause the harm. The cancer did. It's a powerful argument."

In most negligence claims, you must prove on the balance of probabilities (more likely than not) under the Civil Liability Act 1961 that the defendant's negligence caused your injury. In cancer, that's often impossible because survival statistics don't work in binary. A 40% five-year survival rate doesn't mean you'd have survived. That's not how statistics work. It means four in ten people in your position would have. The question is whether the delay reduced your chances, and if so, whether that's compensable.

Irish law sits in an unusual position internationally. Two conflicting Supreme Court decisions remain unreconciled. They haven't been resolved since:

What does this mean for your cancer claim in practice? It's unsettled, and that uncertainty can work for you. Here's why. Your solicitor can argue Philp applies to cancer claims specifically because cancer involves probabilistic survival data in a way that most other injuries don't. The argument runs: where medical science can't say with certainty whether earlier treatment would've saved you, it's unjust to deny compensation for the lost opportunity to try. Fennelly J's reasoning in Philp was specifically about the deprivation of choice and opportunity, not about statistical certainty.

The practical consequence under Philp v Ryan: don't assume your case is hopeless because your cancer was already aggressive. It's not that simple. The relevant question isn't "would you have survived?" It's "did the delay deprive you of a meaningful chance at better treatment, longer life, or informed decision-making about your care?" If the answer is yes, and your expert can quantify what that chance was worth. That's the test, Philp gives you a legal foundation that doesn't exist in England (where Gregg v Scott [2005] UKHL 2 shut the door on sub-50% claims).

This is another area where Ireland's position is more favourable to claimants than England's.

What are the Rapid Access Clinic targets the HSE is missing?

Ireland's National Cancer Strategy 2017 to 2026 sets specific Key Performance Indicators for Rapid Access Clinics (RACs) across eight designated cancer centres. These KPIs aren't aspirational. In a legal context, they define the minimum expected standard of care for urgent cancer referrals.

When nearly one in four women with urgent breast symptoms wait longer than 10 working days, a patient who waited four weeks wasn't experiencing bad luck. That's a systemic failure. They were caught in a documented systemic breach of the HSE's own service plan. That data point, sourced from the HSE itself, becomes powerful evidence that the standard of care wasn't met. The National Cancer Registry Ireland provides the epidemiological context, while the HSE's performance reports document the gap between targets and reality.

Time limits and the date of knowledge rule

The limitation period for cancer misdiagnosis claims in Ireland is two years, but the clock doesn't start on the date of the missed scan or failed referral. It starts on the date of knowledge: the date the claimant knew, or ought reasonably to have known, that they suffered an injury attributable to someone else's negligence. This rule, under the Statute of Limitations 1957 (as amended), is critical in cancer cases because many patients only discover the error years later.

The CervicalCheck scandal illustrates this sharply. Women who received clear smear results in 2009 weren't told about the retrospective audit findings until 2018. Their limitation clock started in 2018, not 2009. Similarly, a patient whose lung nodule was missed on a 2021 CT but who wasn't re-scanned until 2024 may have a date of knowledge in 2024. What the timeline estimates don't account for: the date of knowledge can itself be disputed, and the defence will argue you "ought to have known" earlier based on symptoms or available information.

For claims involving children, the two-year period doesn't begin until the child turns 18. For fatal injury claims, dependants have two years from the date of death under the Civil Liability Act 1961.

HC131 and HC132: the 2025 procedural revolution for cancer claims

Since 28 April 2025, all High Court clinical negligence cases, including cancer misdiagnosis claims, fall under two new Practice Directions that fundamentally change how these cases are managed (Courts Service).

HC132 established a dedicated Clinical Negligence List within the Dublin Personal Injuries List, presided over by a specialist Judge in Charge. Every cancer claim now receives structured case management from a judge experienced in clinical negligence, reducing the inconsistency that previously frustrated both plaintiffs and defendants.

HC131 requires parties to satisfy four conditions before applying for a trial date: fully pleaded cases with all particulars delivered, completed discovery, and exchange of expert reports. Critically, they must commit to offer mediation within three weeks of fixing the trial date and to participate within six weeks of acceptance. This isn't optional. A solicitor must sign a Certificate of Compliance confirming these conditions are met.

The practical impact: cancer claims shouldn't take as long, with fewer "trial by ambush" scenarios where critical expert evidence emerges at the last moment. The 43% mediation rate in clinical claims concluded by the State Claims Agency in 2024 is likely to rise significantly under this new framework.

What does the court require from your expert oncologist?

Cancer misdiagnosis claims live or die on expert evidence, and Irish courts apply strict rules about how that evidence must be presented. Under Order 39, Rules 57 to 61 of the Rules of the Superior Courts, your expert doesn't work for you. They're working for the court.

Rule 57 makes this explicit: the expert's duty to assist the court overrides any obligation to the party paying their fee. Every expert report must contain a written acknowledgment of this duty and must disclose any financial interest the expert has in the party's business or research. In practice, reports that skip this formality don't survive unchallenged.

Rule 61 introduces a requirement that many claimants don't expect. Where opposing experts contradict each other (which happens in virtually every cancer case), the judge can order them to meet privately. You won't be there, without lawyers present, to identify areas of agreement and narrow the issues in dispute. This "hot-tubbing" process means your expert's position can't just hold up under cross-examination. It's got to survive a direct peer-to-peer discussion with the defence expert.

Under HC131, expert reports must now be exchanged before a trial date can be fixed. The old tactic of withholding a key report until the eve of trial isn't available anymore. Combined with Rule 58, which restricts expert evidence to what's "reasonably required," judges aren't tolerating weak or speculative expert testimony the way they used to.

The critical implication for cancer claims: your solicitor should instruct an expert who can withstand both cross-examination and private conferencing with the defence expert. Reports that read as advocacy documents rather than independent analyses won't survive scrutiny.

How is compensation calculated in cancer misdiagnosis claims?

Compensation in Irish cancer misdiagnosis claims doesn't follow a single formula. It's governed by the Personal Injuries Guidelines (2021), formerly the Book of Quantum until 2021, for general damages (pain and suffering), combined with actuarial calculations for special damages (financial losses). Awards aren't fixed, and the figures below aren't predictions. They're indicative ranges from the Guidelines.

The real financial weight in cancer claims isn't in general damages, it's in special damages: cost of ongoing care, loss of earnings (including future loss), medical and travel expenses, home adaptations, and (in fatal cases) dependency claims. In Morrissey, while general damages were €500,000, total compensation reached €2,152,508 once special damages were included. The difference between assessment and settlement in cancer cases often turns on the quality of the actuarial evidence supporting future financial loss.

The Injuries Resolution Board (IRB), formerly the Personal Injuries Assessment Board (PIAB) until 2023, does NOT assess medical negligence claims. Cancer misdiagnosis cases don't go through the IRB. They go directly to the High Court (or Circuit Court for lower-value claims).

Can you get money before your cancer case settles?

Catastrophic cancer claims can take two to four years. For patients who can't work or who're facing terminal diagnoses, waiting isn't realistic. There's no reason to. Irish law provides two mechanisms for early access to funds, and neither is well understood. Most claimants don't know they exist.

Interim payments under Section 51 of the Courts Act 1981 allow the court to order the defendant to pay a sum in advance of final judgment where liability isn't seriously contested and the claimant faces hardship. In cancer claims against the HSE, the State Claims Agency (SCA) manages all settlement decisions, and the SCA will sometimes agree to voluntary interim payments to avoid the costs of a contested application. It's not guaranteed, but the key is demonstrating that liability is strong and that immediate financial need exists.

Lodgements and tender: Separately, the defendant can make a formal offer (a lodgement) at any stage. If you reject it and the court awards less at trial, you may face costs consequences from the date of the lodgement. In cancer cases, where prognosis can change rapidly, early lodgements are sometimes tactically motivated. Your legal team shouldn't assess any offer against the pressure of ongoing bills. It's the up-to-date medical and actuarial evidence that matters.

Who actually defends your cancer claim against the HSE?

When you sue the HSE for cancer misdiagnosis, you aren't negotiating with the hospital. That's a common misconception. The State Claims Agency (SCA), a division of the National Treasury Management Agency, manages all clinical negligence claims against the State. It's a centralised operation. The SCA instructs defence solicitors, appoints defence experts, and makes all settlement decisions. The hospital and its doctors don't control the litigation once it's underway.

This matters practically. The SCA's published data shows that in 2024, 43% of clinical negligence claims were resolved through mediation, and the average time to resolution hasn't stayed static. It's shortened under the new HC131 framework. The SCA also operates a risk management function: it analyses claims data to identify systemic failures in hospitals and recommends changes. In some cases, SCA-funded safety reviews have already identified the error in your case before you even file, and those internal reviews can be discoverable. They're not always hidden.

Something that's poorly understood: the SCA's legal strategy isn't set by the consultant who treated you. Defence decisions are made centrally. They aren't set locally. The treating doctor may've privately accepted the error occurred, but the SCA's appointed defence team may still contest liability if they believe causation is weak. Don't assume a doctor's informal acknowledgement translates to an early settlement. It won't unless the SCA agrees.

Can the hospital reduce your compensation if you missed appointments?

Yes. Under Section 34 of the Civil Liability Act 1961, if you contributed to your own injury through your own negligence, the court can reduce your damages proportionally. In cancer misdiagnosis claims, hospitals raise contributory negligence more often than most claimants expect. It's their second line of defence after causation.

The argument typically takes one of three forms:

Missed follow-up appointments. If the hospital scheduled you for a repeat scan or follow-up consultation and you didn't attend, the defence will argue that earlier detection was available but you didn't take it. The strength of this argument depends on context: were you told the appointment was urgent? Was there a clear explanation of why follow-up was needed? Did the hospital send reminders or attempt to contact you when you didn't show? A patient who wasn't told the follow-up was cancer-related and who didn't receive a reminder is in a very different position from one who ignored explicit warnings.

Delayed presentation to your GP. If you noticed symptoms (a lump, bleeding, unexplained weight loss) and waited months before seeing your GP, the defence may argue your own delay contributed to the staging shift. This argument is weaker than it sounds. The law recognises that patients aren't medical professionals. Attributing a percentage of blame to someone who didn't recognise the significance of vague symptoms is difficult for a defence to sustain unless the symptoms were obvious and you'd been specifically advised to watch for them.

Non-compliance with treatment. In rarer cases, if you declined a recommended biopsy, refused treatment, or discharged yourself against medical advice, the defence may argue your own decisions worsened your outcome. Again, context matters: was the refusal based on inadequate information from the clinician? Did you refuse because of a previous negative experience in the same hospital? Courts look at the reasonableness of the patient's decision. It's not just about what you did. It's about why.

The critical point: contributory negligence doesn't eliminate your claim. It can't. It only reduces it. If the court finds you were 20% responsible for the outcome and your damages are €500,000, you'd receive €400,000. The hospital still pays for its share. That doesn't change. In our experience, contributory negligence arguments in cancer claims rarely succeed at more than 10 to 25% reduction, and many fail entirely because the hospital can't show the patient had enough information to act differently. If you weren't told it was urgent, you can't be blamed for not treating it as urgent.

If you're worried that missing appointments or delaying your GP visit might affect your claim, don't let it stop you from getting advice. It shouldn't. Your solicitor will assess the timeline and advise whether the hospital's contributory negligence argument has any real prospect of succeeding. In most cases, it doesn't change whether you have a viable claim. It only affects the size of the award. That's a very different thing from having no claim at all.

Can family members claim after a cancer death?

Dependants of a person who dies from cancer caused or worsened by misdiagnosis can bring a fatal injury claim under the Civil Liability Act 1961. This includes a solatium (statutory mental distress payment, currently €35,000 total shared among all dependants), plus a dependency claim calculating lost financial support over the deceased's projected working life. In high-earning households, dependency claims can significantly exceed general damages.

The timing matters. Dependants don't have unlimited time: they've two years from the date of death to initiate proceedings, and the date-of-knowledge rule can also apply where the link between negligence and death only becomes apparent later.

CervicalCheck, BreastCheck, and screening-specific claims

Women affected by the CervicalCheck scandal face a choice between the CervicalCheck Tribunal (a statutory alternative) and High Court litigation. The Tribunal was designed to offer a less adversarial process. It hasn't delivered as expected, yet it's faced criticism for delays and has made zero compensation awards as of early 2026. Affected women have needed to pursue court proceedings for actual recovery.

Under the Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023, Part 5 creates a right for patients to request a review of their cancer screening results from BreastCheck, CervicalCheck, or BowelScreen. An important clarification: Part 5 has NOT yet commenced. Parts 1 to 4 (mandatory open disclosure of notifiable incidents) took effect on 26 September 2024, but the Department of Health hasn't yet issued a commencement order for Part 5 screening reviews (Gov.ie, September 2024).

For BreastCheck, the concept of "interval cancer" is central. An interval cancer (one that appears between scheduled screens) often implies the previous mammogram was misread (a false negative). BreastCheck performs retrospective audits on interval cancers, and those audit results can become the key evidence in a claim. The standard of care for mammography requires independent double reading: two radiologists review each image, and disagreement triggers a consensus or arbitration process. Negligence frequently arises when this arbitration isn't followed.

Mandatory open disclosure: what the hospital must tell you after a cancer error

Since 26 September 2024, Parts 1 to 4 of the Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023 require every public and private healthcare provider to disclose certain serious incidents to patients or their families. This isn't voluntary. It's a legal obligation. Non-compliance isn't just a regulatory risk. It carries a criminal fine of up to €5,000.

Schedule 1 of the Act lists 13 notifiable incidents, including unintended death directly related to medical treatment, wrong-site surgery, and medication errors causing death. If your cancer misdiagnosis involved any notifiable incident, the hospital can't avoid holding an open disclosure meeting led by the principal clinician responsible for your care. At that meeting, you're entitled to the date and description of the incident, when it came to the provider's attention, and the physical and psychological consequences (Gov.ie, September 2024).

A critical protection for claimants: under Section 10, any information provided at the disclosure meeting, including any apology, can't constitute an admission of liability, can't invalidate insurance, and isn't admissible as evidence in court proceedings. This means the hospital can be honest without legal exposure from the conversation itself. That's the trade-off the Act creates. For claimants, the information gained at the meeting (while not directly usable as evidence) will often point you toward the records and experts you'll need to build a formal case.

If you decline the open disclosure meeting, the provider must inform you of your right to request it at any point within the next five years. Don't let an initial emotional reaction close this door. It's there for five years.

Ireland vs England and Wales: key legal differences in cancer claims

Irish and English law on medical negligence differ in ways that directly affect cancer claims. For anyone researching cancer misdiagnosis, the differences aren't trivial. Key legislation: Statute of Limitations 1957 (Ireland) and Limitation Act 1980 (England).

The most consequential difference for cancer claims is the limitation period. It's one year shorter in Ireland. The second most consequential is loss of chance: Ireland's position under Philp is more favourable to claimants than England's. Claimants who read UK guidance and assume they've three years, or that a poor prognosis defeats their claim, may be wrong on both counts.

Evidence checklist for cancer misdiagnosis claims

Strong cancer claims aren't built on court filings. They're built on documentation gathered early. Delays in collecting evidence, particularly imaging and pathology, can't be undone and can be fatal to a case.

The cases that succeed are those where records were secured within weeks, not months. Hospital record-keeping isn't perfect, and imaging can be archived or overwritten. Your solicitor should issue preservation letters to every relevant provider immediately.

How do you actually get your medical records in Ireland?

The route to your records depends on whether you're requesting from a public or private provider. It's not the same process, and the timelines differ.

Private hospitals and consultants: Submit a subject access request under the Data Protection Act 2018. The provider has one month to respond (extendable to three months for complex requests). There's no fee for the request itself, though the provider can charge a "reasonable fee" for additional copies. It shouldn't be more than a few euro. In practice, most providers don't take longer than four to six weeks.

HSE / public hospitals: You can use either a Data Protection subject access request or a Freedom of Information (FOI) request under the FOI Act 2014. FOI covers broader categories of records (including internal correspondence and incident reports) but the response deadline is four weeks with a possible extension. The initial FOI request is free for personal records. Many solicitors don't rely on a single route. They'll use both simultaneously: Data Protection for the core medical file, FOI for internal hospital communications about your case.

Imaging and pathology: These often require a separate, targeted request to the radiology or pathology department, specifying the exact dates and modalities. Don't assume your "full medical records" include the actual digital images or tissue slides. They often don't unless you've explicitly asked. Your solicitor should request imaging on disc (DICOM format) and pathology slides for independent expert review.

What happens when your GP and hospital are both at fault?

Cancer misdiagnosis cases frequently involve more than one defendant. A GP who didn't act on red-flag symptoms for months AND a hospital that downgraded an urgent referral to routine can both be liable. In Irish law, this creates concurrent wrongdoers under the Civil Liability Act 1961.

The practical effect: you can claim against both. You don't have to choose. That's the key point. The court apportions liability between the defendants based on their respective contributions to the harm. If the GP's delay contributed 40% and the hospital's missed scan contributed 60%, damages are divided accordingly between them. You're not affected by the split, but you receive the full amount. Each concurrent wrongdoer is liable for the entire sum, so if one can't pay, the other covers the shortfall. You're not left short.

Where this gets complicated in cancer claims is when the GP is insured privately (through a medical defence organisation like the MPS or MDU) while the hospital claim runs through the SCA. The two defence teams don't coordinate, and their litigation strategies often conflict. In practice, the hospital may blame the GP for the initial delay while the GP blames the hospital for not acting on the referral. This finger-pointing can actually help your case. It's not unusual for each side to generate admissions about the other's failures.

What is a Section 8 letter and when must it be sent?

Before issuing proceedings in any personal injury case (including cancer misdiagnosis), your solicitor must send a letter of claim under Section 8 of the Civil Liability and Courts Act 2004. This letter can't be vague. It must set out the nature of the wrong alleged, the injuries claimed, and the circumstances. The defendant then has two months to respond.

In cancer claims, the Section 8 letter serves a dual purpose. It puts the hospital or GP on formal notice, which triggers their obligation to preserve all relevant records and communications. It also starts the clock on their response period. They can't ignore it. If the defendant doesn't respond within two months, the court can take that into account when awarding costs.

A common mistake in cancer cases: sending the Section 8 letter before you've obtained and reviewed the medical records. A premature letter that misidentifies the defendant or misstates the timeline won't help your credibility later. It's better to secure records first, have them reviewed by your expert, and then send a Section 8 letter that accurately reflects the negligence and causation your expert has identified.

What cost information must your solicitor give you before acting?

Under Section 150 of the Legal Services Regulation Act 2015, your solicitor can't start acting without providing written notice of the legal costs involved before taking instructions to act. This notice must include the basis on which costs will be calculated. It's not optional, an estimate of the charges, and details of the circumstances that may result in additional costs.

In cancer misdiagnosis cases, costs can be substantial because expert reports (often from UK-based specialists), actuarial reports, and imaging analysis all carry fees. Section 150 also requires your solicitor to inform you if third-party costs (such as the defendant's costs if you lose) may apply. If your case is being run on a "no win, no fee" arrangement, it's not enough to shake hands on it, the terms of that arrangement should be documented in writing and explain what happens if the case is discontinued or settles for less than expected.

This isn't just a formality. It's enforceable. If your solicitor hasn't complied with Section 150, the Legal Services Regulatory Authority can investigate. It's not a toothless rule, and non-compliance can affect the enforceability of the fee agreement. You're entitled to this information. Don't wait to be told. Ask for it upfront.

Common questions about cancer misdiagnosis claims in Ireland

Answers reflect current Irish law: Civil Liability Act 1961, Personal Injuries Guidelines (2021), Patient Safety Act 2023, and the Dunne/Morrissey line of authority.

Related questions

Sources and references

Case law

1. Morrissey & Anor v HSE & Ors [2020] IESC 6 (Supreme Court, 13 March 2020). Screening negligence and the Dunne standard. BAILII
2. Philp v Ryan & Anor [2004] IESC 105 (Supreme Court, 17 December 2004). Loss of chance in cancer delay. BAILII
3. Quinn (minor) v Mid Western Health Board & Anor [2005] IESC 19 (Supreme Court, 8 April 2005). Traditional causation test. BAILII
4. Gregg v Scott [2005] UKHL 2 (House of Lords, 27 January 2005). Loss of chance rejected in England. BAILII
5. Dunne v National Maternity Hospital [1989] IR 91 (Supreme Court). The standard of care test. Applied in Morrissey

Legislation

1. Statute of Limitations 1957 (as amended). Two-year limitation for personal injuries. Irish Statute Book
2. Civil Liability Act 1961 (as amended). Concurrent wrongdoers, contributory negligence, fatal claims. Irish Statute Book
3. Civil Liability and Courts Act 2004, s.8. Pre-action letter requirement. Irish Statute Book
4. Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023. Open disclosure, notifiable incidents, screening reviews. Irish Statute Book
5. Data Protection Act 2018. Subject access requests for medical records. Irish Statute Book
6. Legal Services Regulation Act 2015, s.150. Costs follow the event. Irish Statute Book

Official guidance and data

1. Judicial Council Personal Injuries Guidelines (2021). Compensation bands for general damages. Judicial Council (PDF)
2. National Cancer Strategy 2017 to 2026. Policy framework for cancer care in Ireland. Gov.ie
3. NCCP GP Referral Guidelines. Red-flag criteria for rapid access clinics. HSE/NCCP
4. National Cancer Registry Ireland. Incidence, survival, and staging data. NCRI
5. State Claims Agency / NTMA 2024 Annual Report. Clinical claims data and mediation rates. SCA
6. Courts Service of Ireland. HC131/HC132 Practice Directions, Clinical Negligence List. Courts.ie
7. Patient Safety Act 2023 commencement notice (26 September 2024). Gov.ie
8. HSE National Screening Service. Part 5 screening review explanation. HSE NSS

Academic sources

1. Peer PG et al. "Age and growth rate of breast cancer." Cancer. 1993, 71(11), 3547-3551. Tumour doubling time study. PubMed